Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence

References

• Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology. 2006;212:327–337.
   PubMed Web of Science ®Google Scholar
• Fuchs BS, Hadi S. Use of. etanercept in the treatment of psoriasis and psoriatic arthritis. Rev Recent Clin Trials. 2006;1:259–263.
   PubMedGoogle Scholar
• Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics. 2008;26:121–129.
   PubMedGoogle Scholar
• Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19:5–21.
   PubMed Web of Science ®Google Scholar
• Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008;159:2–9.
   PubMedGoogle Scholar
• Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2006;8:355–363.
   PubMedGoogle Scholar
• Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64–ii14–ii17.
   Google Scholar
• van de Kerkhof P, Barker J, Griffiths CE, Menter A, Leonardi C, Young M, et al. Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. J Dermatolog Treat. 2011;22:187–193.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG. Use of etanercept in the dermatology setting. A review. Am J Clin Dermatol. 2005;6:49–59.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Matz H. Phototherapy for psoriasis: what to choose and how to use: facts and controversies. Clin Dermatol. 2010;28:73–80.
   PubMedGoogle Scholar
• Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160:810–820.
   PubMed Web of Science ®Google Scholar
• Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:6–10.
   PubMed Web of Science ®Google Scholar
• Warren RB, Griffiths CE. The future of biological therapies. Semin Cutan Med Surg. 2010;29:63–66.
   PubMed Web of Science ®Google Scholar
• Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:17–22.
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:1–70.
   PubMed Web of Science ®Google Scholar
• Foley PA, Quirk C, Sullivan JR, Dolianitis C, Hack SP, Cooper AJ. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. J Eur Acad Dermatol Venereol. 2010;24:1135–1143.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–1632.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–1312.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159:1177–1185.
   PubMed Web of Science ®Google Scholar
• Strohal R, Puig L, Chouela E, Tsai TF, Melin J, Freundlich B, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomized, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2012; Epub ahead of print.
   Google Scholar
• Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719–726.
   PubMed Web of Science ®Google Scholar
• Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007;156:138–142.
   PubMedGoogle Scholar
• Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9:928–937.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Gottlieb AB, Leonardi CL, Elewski CL, Wang A, Jahreis A, Zitnik R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006;17:9–17.
   PubMed Web of Science ®Google Scholar
• Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598–603.
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Griffiths C, Daudén E, Strohal R, Robertson D, Pedersen R, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Exp Rev Dermatol. 2008;3:657–659.
   Google Scholar
• Ortonne JP, Taieb A, Ormerod AD, Robertson D, Foehl J, Pedersen R, Molta C, Freundlich B. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol. 2009;161:1190–1195.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–251.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, Kricorian G. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63:762–768.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010;63:769–774.
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154:181–183.
   PubMed Web of Science ®Google Scholar
• Segaert S. Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update. J Inflamm Res. 2009;2:29–36.
   PubMedGoogle Scholar
• Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
   PubMed Web of Science ®Google Scholar
• Pfizer. Enbrel®25 mg powder and solvent solution for injection: summary of product characteristics. Available from http://www.medicines.org.uk/emc/medicine/3343/SPC. Last accessed 12 October 2011.
   Google Scholar
• Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009;102:1133–1140.
   PubMed Web of Science ®Google Scholar
• Dixon W, Hyrich KL, Watson K, Lunt M. The influence of anti-TNF therapy upon the incidence and severity of serious lower respiratory tract infections in patients with rheumatoid arthritis: results from the BSR biologics register (BSRBR) [abstract no. 157]. Rheumatology (Oxford). 2008;47:ii47.
   Google Scholar
• Dixon WG, Hyrich KL, Watson KD, Lunt M. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522–528.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331–2339.
   PubMed Web of Science ®Google Scholar
• Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648–653.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886–2895.
   PubMed Web of Science ®Google Scholar
• Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69:400–408.
   PubMed Web of Science ®Google Scholar
• Bachmann F, Kokolakis G, Sterry W, Philipp S. Etanercept: overview of clinical experience in the treatment of psoriasis and psoriatic arthritis. Int J Clin Rheumatol. 2011;6:135–155.
   Google Scholar
• Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
   PubMed Web of Science ®Google Scholar